Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial

Background: We assessed the cost-effectiveness of single-inhaler fl uticasone furoate (FF)/ umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513)

[1]  J. Scullion,et al.  When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals , 2019, International journal of chronic obstructive pulmonary disease.

[2]  A. Ismaila,et al.  Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. , 2018, Respiratory medicine.

[3]  F. Martinez,et al.  Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT , 2018, Pneumologie.

[4]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[5]  M. Beauchesne,et al.  CTS position statement: Pharmacotherapy in patients with COPD—An update , 2017 .

[6]  A. Ismaila,et al.  Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  A. Briggs,et al.  Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  A. Ismaila,et al.  Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Reiner Leidl,et al.  External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  A. Ismaila,et al.  Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review , 2015, BMC Research Notes.

[11]  A. Ismaila,et al.  Validating A Model To Predict Disease Progression Outcomes In Patients With COPD. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  A. Briggs,et al.  Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  P. Jones,et al.  Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification , 2012, European Respiratory Journal.

[14]  T. Welte,et al.  Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease , 2011, PharmacoEconomics.

[15]  A. Briggs,et al.  Predicting EQ-5D values using the SGRQ. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  R. Hoogenveen,et al.  Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[18]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[19]  A. Briggs,et al.  Pharmacoeconomics in COPD: lessons for the future , 2008, International journal of chronic obstructive pulmonary disease.

[20]  D. Mannino,et al.  Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. , 2008, Archives of internal medicine.

[21]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[22]  B. Monz,et al.  Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? , 2006, Chest.

[23]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[24]  A. Ismaila,et al.  Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective , 2019, Respiratory Medicine: X.

[25]  M. Sadatsafavi,et al.  The global economic burden of asthma and chronic obstructive pulmonary disease. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[26]  A. Briggs,et al.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease , 2012, PharmacoEconomics.

[27]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[28]  Jennifer Long,et al.  A New Method for Database Data Quality Evaluation at the Canadian Institute for Health Information (CIHI) , 2002, ICIQ.

[29]  Murry Foss,et al.  Consumer Price Index , 1993 .

[30]  F. Martinez,et al.  American Journal of Epidemiology Practice of Epidemiology the Association between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: an Application of a Joint Frailty-logistic Model , 2022 .